• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: LUTRONIC CORPORATION CLARITY II

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

LUTRONIC CORPORATION CLARITY II Back to Search Results
Medical Device Problem Code Environmental Particulates (2930)
Health Effect - Clinical Code Skin Inflammation/ Irritation (4545)
Date of Event 12/18/2025
Type of Reportable Event Malfunction
Event or Problem Description
It was reported that during vessel treatment on the nose and cheeks, a loud "pop" sound was heard followed by a spark and a black soot mark was left on the patient.The soot was wiped away and when the patient returned for follow-up treatment approximately a month later, there was a red circle on the nose that started to scab.A trained cynosure lutronic field service engineer went to the treatment provider site for a device evaluation.During this time, the reported issue was unable to be duplicated.The device was subjected to multiple tests including full functionality testing, energy tests and full visual inspection with no discrepancies observed.The device was found to be working within published specifications.It is undetermined what caused the reported incident.A member of the cynosure lutronic clinical team made contact with the treatment provider and determined that the provider treated the patient with an off label indication at their own discretion.It is unknown if this contributed to the reported loud pop, spark and black mark that was reported to be left on the patient, or the red mark that remained on the patients nose one month post treatment.To reduce the probability of reoccurrence, the most recent device quick start guide was sent to the treatment site.Cryogen is applied to the treatment site during vascular treatment to precool the skin.The cryogen begins to vaporize from the surface of the skin shortly after contact.The laser fires onto the surface of the skin after a delay time.The spark/ignition events occur when residual cryogen vapors remaining on the skin surface interact with the high-energy 1064 nm laser fluence.Longer pre-cooling and delay times increase the likelihood of uneven vapor accumulation, thereby elevating the risk of ignition.This can be observed as a spark and can result in topical burn.The event is reportable per fda medical device reporting title 21 cfr part 803 since a malfunctioned occurred and would likely cause or contribute to a serious injury if the malfunction were to recur.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CLARITY II
Common Device Name
CLARITY II
Manufacturer (Section D)
LUTRONIC CORPORATION
lutronic center
219, sowon-ro
deogyang-gu, goyang-si 10534
KS  10534
MDR Report Key24507900
Report Number1222993-2026-00013
Device Sequence Number13247595
Product Code GEX
UDI-Device Identifier08809447653723
UDI-Public(01)08809447653723(11)250220
Combination Product (Y/N)N
Initial Reporter CountryCA
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Importer
Initial Reporter Occupation Other
Type of Report Initial
Report Date (Section B) 03/04/2026
Report Date (Section F) 03/04/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Was Device Available for Evaluation? Yes
Was the Report Sent to FDA? Yes
Event Location Outpatient Treatment Facility
Initial Date Received by Manufacturer Not provided
Initial Report FDA Received Date03/04/2026
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Other;
Patient Age59 YR
Patient SexFemale
Date Report Sent to FDA03/04/2026
-
-